Pharma Sector

As per USFDA, the facility did not thoroughly analyse contamination across medicine batches and continued to issue compromised items.

The USFDA has also noted a repeat observation from the company's January 2023 inspection.

Eugia Steriles, a 100% subsidiary of Eugia Pharma Specialities and a step down arm of Aurobindo Pharma, operates the new plant.

In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.

According to the firm, the NDA submission package is based on three clinical trials, many pre-clinical investigations.

Natco Pharma disclosed that its subsidiary will invest USD 8 million in eGenesis, acquiring a total of 40,629,761 shares.

The transaction was finalised on August 26, 2024, through a share purchase agreement, subject to approval from IRDAI.

The USFDA has also approved Biocon Limited subsidiary's ANDA for Daptomycin for Injection (500mg Vial) for skin infections.

On another hand, the company logged a net profit of ₹23.9 Crore in the June quarter, down 52.2% from last year's ₹50 Crore.

In FY24, Paramount TPA collected ₹3,866 Crore in premiums from the group and retail divisions, resulting in a revenue of ₹153 Crore.